Abstract:Cisplatin is a common platinum-based chemotherapeutic that induces acute kidney injury (AKI) in about 30% of patients. Pharmacokinetic/toxicodynamic (PKTD) models of cisplatin-induced AKI have been used to understand risk factors and evaluate potential mitigation strategies. While both traditional clinical biomarkers of kidney function [e.g., serum creatinine (SCr), blood urea nitrogen (BUN), estimated glomerular filtration rate (eGFR), and creatinine clearance (CrCl)] and newer subclinical biomarkers of kidney injury [e.g., urinary kidney injury molecule 1 (KIM-1), beta-2 microglobulin (B2M), neutrophil gelatinase-associated lipocalin (NGAL), calbindin, etc.] can be used to detect cisplatin-induced AKI, published PKTD models are limited to using only traditional clinical biomarkers. Previously identified risk factors for cisplatin nephrotoxicity have included dose, age, sex, race, body surface area, genetics, concomitant medications, and comorbid conditions. However, the relationships between concentrations and the pharmacokinetics (PK) of platinum and biomarkers of kidney injury have not been well elucidated. This review discusses the evaluation of cisplatin-induced nephrotoxicity in clinical studies, mouse models, and in vitro models, and examines the available human PK and toxicodynamic (TD) data. Improved understanding of the relationships between platinum PK and TD, in the presence of identified risk factors, will enable the prediction and prevention of cisplatin kidney injury. SIGNIFICANCE STATEMENT: As cisplatin treatment continues to cause AKI in a third of patients, it is critical to improve the understanding of the relationships between platinum PK and nephrotoxicity as assessed by traditional clinical and contemporary subclinical TD markers of kidney injury. Prediction and prevention of cisplatin-induced nephrotoxicity will be advanced by the evolving development of PKTD models that incorporate kidney injury biomarkers with enhanced sensitivity and include covariates that can impact risk of developing cisplatin-induced AKI.

Mechanism of Platinum Derivatives Induced Kidney Injury

Molecular Mechanisms of Chemoresistance and Cytotoxicity Associated with Platinum Drugs

The renal damage and mechanisms relevant to antitumoral drugs

Mechanism of Kidney Injury Induced by Cisplatin

Preventive Effect of Meglumine on Rat's Nephrotoxicity Induced by Cisplatin and Discussion on Its Mechanism

Platinum-based chemotherapies-induced nephrotoxicity: mechanisms, potential treatments, and management

Mitochondrial Superoxide Dismutase in Cisplatin-Induced Kidney Injury

Mechanisms of Cisplatin-Induced Acute Kidney Injury: Pathological Mechanisms, Pharmacological Interventions, and Genetic Mitigations

An integrative view of cisplatin-induced renal and cardiac toxicities: Molecular mechanisms, current treatment challenges and potential protective measures

Cellular processing of platinum anticancer drugs

Adverse reactions, prevention and treatment of platinum compounds

The Drug-Resistance Mechanisms of Five Platinum-Based Antitumor Agents.

The toxicity of cisplatin derives from effects on renal organic ion transporters expression and serum endogenous substance levels

The side effects of platinum-based chemotherapy drugs: a review for chemists.

Progress in the study of reproductive toxicity of platinum-based antitumor drugs and their means of prevention

Understanding Cisplatin Pharmacokinetics and Toxicodynamics to Predict and Prevent Kidney Injury

Cisplatin nephrotoxicity: new insights and therapeutic implications

Review of the toxicological mechanism of anticancer drug cisplatin

Inhibition of Thioredoxin Reductase 1 Correlates with Platinum-Based Chemotherapeutic Induced Tissue Injury.

Molecular mechanisms of cisplatin-induced nephrotoxicity: a balance on the knife edge between renoprotection and tumor toxicity